Phase 3 Type 2 Diabetes Trial, Recruiting NCT05776420 Sponsor: Unity Health Toronto Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT05776420
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose HbA1c blood sugar level (a measure of average blood sugar over roughly 3 months) falls between 6.0 and 11.0
  • People who report having difficulty affording enough food or managing their finances

Who may not be able to join:

  • People who already live with someone currently enrolled in this study
  • People with a life expectancy of less than 6 months
  • People who have multiple life-threatening allergies to common foods
  • People who require all of their nutrition to be delivered directly into a vein (rather than eating or drinking)
  • People who have a blood condition that affects how accurately their average blood sugar level can be measured
  • People whose HbA1c blood sugar level is above 11

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 416-864-6060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Unity Health Toronto
Registry
ClinicalTrials.gov
Start date
21 March 2023
Est. completion
1 April 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Hemoglobin A1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov